Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US2546041011
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00W9MJK79
IRON
Disc Medicine Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Disc Medicine Inc
ISIN
US2546041011
TICKER
IRON
MIC
XNAS
REUTERS
IRON.OQ
BLOOMBERG
IRON US
Do., 27.02.2025       Disc Medicine
US2546041011

WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the fourth quarter and full year ended Dec...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Do., 23.01.2025       Disc Medicine
US2546041011

WATERTOWN, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of its upsized underwritten offering of sha...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Di., 21.01.2025       Disc Medicine
US2546041011

WATERTOWN, Mass., Jan. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference call to discuss feedback received from its Type C meetin...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Fr., 17.01.2025       Disc Medicine
US2546041011

WATERTOWN, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the grant of an inducement equity award to a new employee, effe...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Fr., 10.01.2025       Disc Medicine
US2546041011

WATERTOWN, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today outlined its recent pipeline and operational progress and strategic prior...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Mo., 09.12.2024       Disc Medicine
US2546041011

WATERTOWN, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today spotlights 8 posters presented at the ASH 2024 annual meeting in San Dieg...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Mo., 09.12.2024       Disc Medicine
US2546041011

WATERTOWN, Mass., Dec. 08, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive updated results from a Phase 1b trial of DISC-0974 in...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Di., 12.11.2024       Disc Medicine
US2546041011

WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the third quarter ended September 30, 2024...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Fr., 01.11.2024       Disc Medicine
US2546041011

WATERTOWN, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference call to discuss feedback received from its end-of-Phase...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Fr., 25.10.2024       Disc Medicine
US2546041011

WATERTOWN, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive additional data from an ongoing Phase 1b study of DISC...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Fr., 11.10.2024       Disc Medicine
US2546041011

WATERTOWN, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced upcoming clinical data to be presented at the 2024 American Soc...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Fr., 30.08.2024       Disc Medicine
US2546041011

WATERTOWN, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at f...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Do., 08.08.2024       Disc Medicine
US2546041011

WATERTOWN, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the second quarter ended June 30, 2024....
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Fr., 14.06.2024       Disc Medicine
US2546041011

WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of an underwritten offering of 4,944,000 sh...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Di., 14.05.2024       Disc Medicine
US2546041011

WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple programs in its hematolo...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Do., 09.05.2024       Disc Medicine
US2546041011

WATERTOWN, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the first quarter ended March 31, 2024....
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink